SAR447971 First-in-human Study
← catalyst calendarNCT07629336 · readout in 546 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Kymera Therapeutics, Inc..
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
114estimated
Sites
1
Country
Netherlands
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-26 | actual | When the study began enrolling |
| Primary completion | 2028-02-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-16 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hidradenitis
- Healthy Volunteers
Interventions
- Drug: SAR447971 — also filed as KT-485
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFSAD20411: Incidence of treatment emergent adverse events (TEAEs)
measured Day 1 to Day 15
SAD20411: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)
measured Day 1 to Day 15
SAD20411: Incidence of clinically significant abnormalities in vital signs
measured Day 1 to Day 15
SAD20411: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)
measured Day 1 to Day 15
MAD20412: Incidence of treatment emergent adverse events (TEAEs)
measured Day 1 to Dat 29
MAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)
measured Day 1 to Dat 29
MAD20412: Incidence of clinically significant abnormalities in vital signs
measured Day 1 to Dat 29
MAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)
measured Day 1 to Dat 29
MAD24339: Incidence of treatment emergent adverse events (TEAEs)
measured Day 1 to Day 42
MAD24339: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)
measured Day 1 to Day 42
MAD24339: Incidence of clinically significant abnormalities in vital signs
measured Day 1 to Day 42
MAD24339: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)
measured Day 1 to Day 42
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed